Clinic
Beverly Hills Oncology Medical Group INC
Beverly Hills Oncology Medical Group INC was paid $6.11M by Medicaid between Jan 2018 and Dec 2024, across 68 billing codes. Its largest line is 78815, Positron emission tomography (PET) for limited area imaging — 27% of everything it billed.
33Billing provider infoBEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BEVERLY HILLS, CA 90211
BEVERLY HILLS, CA 90211
33aNPI1427256957assigned 07/05/2007
33bProvider typeRadiology Clinic/Center
28Total paid$6.11M
24GClaims191,305
24DCodes billed68
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Radiology Clinic/Center providers in California
Rank by total paid#5 of 94
Median peer was paid$120K
This provider vs. median51×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 16,752 | $433K | |
| 2019 | 26,919 | $1.08M | |
| 2020 | 33,690 | $1.32M | |
| 2021 | 34,774 | $1.17M | |
| 2022 | 27,400 | $899K | |
| 2023 | 27,763 | $918K | |
| 2024incomplete | 24,007 | $290K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 78815 | Positron emission tomography (PET) for limited area imaging | 27% | 2,654 | 2,598 | $1.67M |
| G6015 | Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 15% | 8,077 | 870 | $908K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7.7% | 16,109 | 14,068 | $467K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 7.1% | 3,685 | 3,465 | $434K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 7.0% | 3,257 | 3,141 | $427K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 5.9% | 8,470 | 7,167 | $363K |
| G6002 | Stereoscopic x-ray guidance for localization of target volume for the delivery of radiation therapy | 3.2% | 12,495 | 1,059 | $197K |
| 96367 | 3.2% | 3,585 | 2,058 | $194K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.5% | 6,888 | 4,277 | $153K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 2.3% | 616 | 573 | $142K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.2% | 28,282 | 21,243 | $132K |
| 80053 | Comprehensive metabolic panel | 2.0% | 20,495 | 15,820 | $121K |
56 more codes
| 77301 | 1.5% | 261 | $94K | |
| 99205 | Prolong outpt/office vis | 1.4% | 1,369 | $88K |
| 77014 | 1.2% | 2,108 | $72K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,214 | $56K |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,696 | $56K |
| 96417 | <1% | 1,863 | $49K | |
| 77334 | <1% | 1,156 | $49K | |
| 77336 | <1% | 2,904 | $44K | |
| 77427 | <1% | 1,762 | $42K | |
| 78816 | <1% | 48 | $35K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,334 | $32K |
| 80047 | <1% | 7,163 | $30K | |
| 77300 | <1% | 597 | $30K | |
| 77338 | <1% | 357 | $28K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,487 | $25K |
| 80076 | <1% | 6,947 | $23K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 461 | $17K |
| G6012 | Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev | <1% | 182 | $16K |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | <1% | 25,471 | $16K |
| 70491 | <1% | 96 | $14K | |
| 77263 | <1% | 429 | $14K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 676 | $14K |
| 96415 | <1% | 533 | $10K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 43 | $8K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,083 | $7K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 117 | $6K |
| 96402 | <1% | 581 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 278 | $4K |
| 72197 | <1% | 16 | $3K | |
| 96416 | <1% | 108 | $3K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 479 | $3K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 91 | $2K |
| 74183 | <1% | 16 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 461 | $1K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 26 | $842.84 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 527 | $519.23 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 28 | $474.52 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 138 | $360.30 |
| 99000 | <1% | 42 | $124.43 | |
| 81002 | <1% | 568 | $100.98 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 17 | $46.24 |
| 82310 | <1% | 53 | $41.10 | |
| A9573 | Injection, gadopiclenol, 1 ml | <1% | 181 | $33.40 |
| 83615 | <1% | 173 | $31.97 | |
| 82947 | <1% | 61 | $31.31 | |
| 82540 | <1% | 52 | $26.26 | |
| 82378 | <1% | 41 | $16.68 | |
| 96523 | <1% | 112 | $15.40 | |
| 82977 | <1% | 54 | $12.68 | |
| 99072 | <1% | 18 | $3.63 | |
| 84520 | <1% | 53 | $2.56 | |
| 83540 | 0% | 15 | $0.00 | |
| 77290 | 0% | 12 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 21 | $0.00 |
| 82728 | 0% | 15 | $0.00 | |
| 86769 | 0% | 98 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGABAYAN, ARASH (PRESIDENT)
Parent organizationBEVERLY HILLS ONCOLOGY MEDICAL GROUP INC